Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/ADPT
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Adaptive Biotechnologies Corp (ADPT) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

ADPT trades at $27.67, up 11.66% today and near its 52-week high. The stock is technically bullish with strong moving average signals, though RSI suggests overbought conditions. Fundamentally, revenue grew to $277M in 2025 with improving margins, but net losses persist. Recent Q2 2026 earnings missed EPS estimates despite revenue beats. The company is transitioning to a pure-play MRD diagnostics business after a strategic separation, highlighted in recent conference presentations (Morgan Stanley Global Healthcare Conference, September 2026).
Outlook is mixed: analyst consensus is Buy (65%) with a $24.38 target, but current price exceeds this. Growth in MRD diagnostics and margin improvements offer upside, yet sustained losses, high valuation multiples (P/S 13.44), and insider selling pose risks. Investors should weigh operational progress against profitability challenges.
Read full analysis

Key Stats

  • Market Cap
    $4.42B
  • Volume
    5,026,085
  • Sector
    Health
  • 52W High
    $27.67
  • 52W Low
    $12.41
  • Typical Hold Time
    36 Days
  • Enterprise Value
    $4.49B
  • Div Yield
    -
  • Trading Activity
    99% Sell | 1% Buy
$28.3
52W Low: $12.41
27 Mar 2026
52W High: $28.3
17 Sep 2026

Track Adaptive Biotechnologies Corp (ADPT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $12.41 and a high of $28.3, highlighting its annual price range. Buy and sell Adaptive Biotechnologies Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Most Recent News

Content is generated by Aura AI

ON Semiconductor drives AI and EV growth with new power tech and a 2030 vision despite neutral rating.

ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...

Market News
1 hour ago
Andrew Wynn
Bearish
news icon
ON Semiconductor drives AI and EV growth with new power tech and a 2030 vision despite neutral rating.

Salesforce targets $63B revenue by 2030, boosted by new AIforce platform and strong analyst support.

Salesforce, a leader in cloud-based CRM software, is driving future growth with its new AIforce platform and ambitious financial goals. The company aims to exceed $63 billion in revenue by 2030, reflecting strong demand for its AI and core software p...

Market News
2 hours ago
Gordon Thompson
Bullish
news icon
Salesforce targets $63B revenue by 2030, boosted by new AIforce platform and strong analyst support.

Oscar Health stock jumps 126% on strong ACA enrollment growth and improved financial outlook

Oscar Health's stock has surged 126% this year, driven by a 47% increase in ACA marketplace enrollment despite overall market declines. The company, now the second-largest insurer on the ACA exchange, has raised its earnings outlook and improved its ...

Market News
3 hours ago
Tony Dante
Bullish
news icon
Oscar Health stock jumps 126% on strong ACA enrollment growth and improved financial outlook
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $4.42B
  • Volume
    5,026,085
  • Sector
    Health
  • 52W High
    $27.67
  • 52W Low
    $12.41
  • Typical Hold Time
    36 Days
  • Enterprise Value
    $4.49B
  • Div Yield
    -
  • Trading Activity
    99% Sell | 1% Buy
$28.3
52W Low: $12.41
27 Mar 2026
52W High: $28.3
17 Sep 2026

Track Adaptive Biotechnologies Corp (ADPT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $12.41 and a high of $28.3, highlighting its annual price range. Buy and sell Adaptive Biotechnologies Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!